Here's why Eli Lilly is a no-brainer stock to buy on the dip. Concerns about Lilly's Q3 update ... company incurred in Q3 ...

One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in ...

The company reported revenue of $11.4 billion and adjusted earnings of $1.18 per share, well below the consensus estimates of $12.1 billion and $1.45, respectively.

Eli Lilly’s (NYSE: LLY ... grew by 17% and will accelerate in Q4 due to the latest acquisition. Morphic Holding is focused on inflammatory bowel disease, a market worth roughly $22 billion ...

In this example, the acquisition of Morphic in August led to a $3.08 ... This is not a good time to buy Eli Lilly stock, but selling now probably isn't the right move either.

Deutsche Bank analyst James Shin has lowered his price target slightly for Eli Lilly, reducing it from $1,025 to $1,015.

Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to ...

Here's why Eli Lilly is a no-brainer stock to buy on the dip ... in Q3 that were primarily related to its acquisition of Morphic Holding. Without this acquisition, Lilly almost certainly wouldn ...

Morphic Holding is focused on inflammatory ... contrary to injectable Zepbound. The article "Is Eli Lilly a Buy? Analyst Confidence Grows for 2025" first appeared on MarketBeat.